Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 28, 2007. The report announces a change to the Board of Directors, specifically the appointment of Professor Sir Roy Anderson as a Non-Executive Director effective October 1, 2007.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance announcement and does not contain financial performance data.
Material Changes
The primary material change is the addition of Professor Sir Roy Anderson to the Board of Directors. He brings expertise in infectious disease epidemiology and will provide insights into scientific developments outside GSK. The Board has determined that Professor Anderson is independent in accordance with the Combined Code on Corporate Governance.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to Chairman Sir Christopher Gent's statement welcoming Professor Anderson and outlining his role in supporting the research and development organization.
Key Facts for Investor Verification
- Professor Sir Roy Anderson joins the Board as an Independent Non-Executive Director on October 1, 2007.
- Professor Anderson is currently Professor of Infectious Disease Epidemiology at Imperial College, London.
- He previously served as Chief Scientific Advisor to the UK's Ministry of Defence until September 30, 2007.
- He is scheduled to succeed Sir Richard Sykes as Rector of Imperial College in the summer of 2008.
- The filing does not include financial results; investors should refer to GSK's Form 20-F or quarterly reports for financial data.